Evidence map›Paper›PMID 35339638›Full record

ArticleThe Journal of hospital infection2022

Reducing broad-spectrum antibiotic use in intensive care unit between first and second waves of COVID-19 did not adversely affect mortality.

X H S Chan, C J O'Connor, E Martyn, A J Clegg, B J K Choy, A L Soares, R Shulman, N R H Stone, S De, J Bitmead and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of hospital infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

X H S ChanDepartment of Clinical Microbiology, University College London NHS Foundation Trust, London, UK; Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
C J O'ConnorDepartment of Clinical Microbiology, University College London NHS Foundation Trust, London, UK.
E MartynDepartment of Clinical Microbiology, University College London NHS Foundation Trust, London, UK; London School of Hygiene and Tropical Medicine, London, UK.
A J CleggDepartment of Clinical Microbiology, University College London NHS Foundation Trust, London, UK.
B J K ChoyDepartment of Clinical Microbiology, University College London NHS Foundation Trust, London, UK.
A L SoaresDepartment of Clinical Microbiology, University College London NHS Foundation Trust, London, UK.
R ShulmanDepartment of Critical Care, University College London NHS Foundation Trust, London, UK; Department of Pharmacy, CMORE, University College London NHS Foundation Trust, London, UK.
N R H StoneDepartment of Clinical Microbiology, University College London NHS Foundation Trust, London, UK.
S DeDepartment of Clinical Microbiology, University College London NHS Foundation Trust, London, UK.
J BitmeadDepartment of Infection Control, University College London NHS Foundation Trust, London, UK.
L HailDepartment of Infection Control, University College London NHS Foundation Trust, London, UK.
D BrealeyDepartment of Critical Care, University College London NHS Foundation Trust, London, UK; Bloomsbury Institute for Intensive Care Medicine, University College London, London, UK.
N ArulkumaranDepartment of Critical Care, University College London NHS Foundation Trust, London, UK; Bloomsbury Institute for Intensive Care Medicine, University College London, London, UK.
M SingerDepartment of Critical Care, University College London NHS Foundation Trust, London, UK; Bloomsbury Institute for Intensive Care Medicine, University College London, London, UK.
A P R WilsonDepartment of Clinical Microbiology, University College London NHS Foundation Trust, London, UK. Electronic address: peter.wilson9@nhs.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic increased the use of broad-spectrum antibiotics due to diagnostic uncertainty, particularly in critical care. Multi-professional communication became more difficult, weakening stewardship activities.

aimTo determine changes in bacterial co-/secondary infections and antibiotics used in COVID-19 patients in critical care, and mortality rates, between the first and second waves.

methodsProspective audit comparing bacterial co-/secondary infections and their treatment during the first two waves of the pandemic in a single-centre teaching hospital intensive care unit. Data on demographics, daily antibiotic use, clinical outcomes, and culture results in patients diagnosed with COVID-19 infection were collected over 11 months.

findingsFrom March 9

conclusionReduced broad-spectrum antimicrobial use in the second wave of COVID-19 compared with the first wave was not associated with significant change in mortality.

Indexed as

Anti-Infective AgentsBacterial InfectionsCoinfectionCOVID-19 Drug TreatmentAnti-Bacterial AgentsHumansIntensive Care UnitsPandemicsSARS-CoV-2Anti-Bacterial AgentsAnti-Infective AgentsAntimicrobial stewardshipBacteraemiaCo-infectionCOVID-19Pseudomonas aeruginosa

Identifiers

PMID35339638
PMCPMC8940720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.